Strategic Partnerships Tollo Health’s recent acquisition of Provista Diagnostics and collaboration with NFL Alumni Health creates opportunities to cross-sell TBIA cancer screening and Videssa breast test through established CLIA/CAP lab capabilities and a broad health-focused network.

Clinical Diagnostic Adds With CE-marked cancer screening tests (TMB-1, TMB-2) and LymPro neurodegenerative test, there is potential to position end-to-end diagnostic portfolios to hospitals and clinics seeking multi-disease screening pipelines and peripheral blood-based assays.

Growth in AI Health The DataMeds AI partnership and Health Lives Here initiative provide a channel to integrate AI-driven health insights and telehealth services with Tollo’s diagnostics, enabling upsell of digital health solutions and data-enabled monitoring programs.

Market Expansion Global distribution agreements for COVID-19 test kits indicate readiness to scale, suggesting sales opportunities to expand into international markets with established suppliers and validation frameworks for rapid deployment.

Niche Neuro ID LymPro and neurodegenerative test development open doors to healthcare systems prioritizing early detection of Alzheimer’s and related conditions, presenting a pathway to secure institutional pilots and reimbursement discussions.